Real‐World Safety and Effectiveness of Evolocumab in Japanese Patients With Familial Hypercholesterolemia: Postmarketing Survey Analysis
Journal of the American Heart Association · 18.11.2026
DOI: 10.1161/jaha.126.050177 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, online erschienen am 18.11.2026. Verfasst von Masatsune Ogura und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Technology, Faculty of Medical Science Juntendo University Chiba Japan. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Background
Evidence on the real‐world use of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors in familial hypercholesterolemia (FH) remains limited. This postmarketing surveillance study (NCT02808403) evaluated Japanese patients with FH and the long‐term real‐world effectiveness of evolocumab.
Methods
This analysis included patients with heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). Diagnostic pathways, patient characteristics, background lipid‐lowering therapy, evolocumab use, low‐density lipoprotein cholesterol (LDL‐C) reduction, long‐term target achievement, and findings in pediatric HoFH were assessed.
Results
Of 2117 patients in the safety analysis set (HeFH, n=2009; HoFH, n=108), 1380 (HeFH, n=1296; HoFH, n=84) were included in the effectiveness analysis. Compared with patients with HeFH, patients with HoFH had higher genetic testing rates (40.7% versus 9.8%), higher mean baseline LDL‐C levels (188.4±107.3 mg/dL versus 139.2±58.3 mg/dL), and higher lipoprotein apheresis use (26.9% versus 2.1%), but fewer total comorbidities (2.2±1.5 versus 2.7±1.5). Statin use was similarly high in patients with HeFH and HoFH (92.2% and 93.5%, respectively) with many patients receiving low‐ to moderate‐intensity statins. Most patients received evolocumab biweekly. LDL‐C reductions were evident at 4 weeks and sustained at 104 weeks. At 104 weeks, mean LDL‐C changes from baseline were −54.0% in patients with HeFH and −48.9% in patients with HoFH. LDL‐C
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Laboratory Technology, Faculty of Medical Science Juntendo University Chiba Japan.
- Medical Affairs Amgen K.K. Tokyo Japan.
- Department of Cardiovascular Medicine Kanazawa University Graduate School of Medical Sciences Kanazawa Japan.
- Cardiovascular Center Osaka Medical and Pharmaceutical University Osaka Japan.
ORCID-Profile: Masatsune Ogura, Nobuhiro Osada
Zitieren
APA
Ogura, M., Yamashita, T., Osada, N., Sheng, F., Tada, H., & Harada-Shiba, M. (2026). Real‐World Safety and Effectiveness of Evolocumab in Japanese Patients With Familial Hypercholesterolemia: Postmarketing Survey Analysis. Journal of the American Heart Association. https://doi.org/10.1161/jaha.126.050177
Vancouver
Ogura M, Yamashita T, Osada N, Sheng F, Tada H, Harada-Shiba M. Real‐World Safety and Effectiveness of Evolocumab in Japanese Patients With Familial Hypercholesterolemia: Postmarketing Survey Analysis. Journal of the American Heart Association. 2026. doi:10.1161/jaha.126.050177
BibTeX
@article{Ogura2026,
author = {Ogura, Masatsune and Yamashita, Takahiro and Osada, Nobuhiro and Sheng, Feng and Tada, Hayato and Harada-Shiba, Mariko},
title = {Real‐World Safety and Effectiveness of Evolocumab in Japanese Patients With Familial Hypercholesterolemia: Postmarketing Survey Analysis},
journal = {Journal of the American Heart Association},
year = {2026},
doi = {10.1161/jaha.126.050177}
}
EUVIMED